ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trospium chloride

Also written as “Xanomeline/trospium chloride”, “Xanomeline/Trospium Chloride Capsule” and “Xanomeline/Trospium Chloride”.

Its studies are mostly in Schizophrenia · Urinary Bladder, Overactive · Alzheimer Disease · Mania · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageTrospium chloride: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 13, 202515 company-led studies, 7 open or runningNext primary completion: Dec 3, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only97 open or runningphase 4since Oct 13, 2025Jul 6, 2016Dec 3, 2026phase 1 · NCT07204418
AbbVie50 open or runningphase 4since Mar 16, 2009Mar 16, 2009none ahead
Keenova Therapeuticsits history only10 open or runningphase 2since Apr 24, 2007Apr 24, 2007none ahead

Also a collaborator on its studies: Alkermes.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2009First study: phase 4 study in Urinary Bladder, OveractiveFirst studyNCT00863551 · 12 enrolled · United States
  2. Jul 1, 2009Phase 4 study in ObesityNCT00932022 · 127 enrolled · United States
  3. Sep 16, 2009Phase 1 study in HealthyNCT00986401 · 44 enrolled · United States
  4. Mar 17, 2010Phase 4 study in Urinary Bladder, OveractiveNCT01089751 · 322 enrolled · United States
  5. Aug 9, 2010Phase 4 study in Urinary Bladder, OveractiveNCT01178827 · 20 enrolled · United States

TargetBeta

CHRM2 →CHRM3 →read by rule
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
trospiumruleBristol-Myers Squibbphase 421
AtropineruleLaboratorios Sophia S.A de C.V.phase 317

Studies

All 5 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01178827Urinary Bladder, Overactive · United States4CompletedMar 201120
NCT01089751Urinary Bladder, Overactive · United States4CompletedJun 2012322
NCT00986401Healthy · United States1CompletedNov 200944
NCT00932022Obesity · United States4CompletedDec 2011127
NCT00863551Urinary Bladder, Overactive · United States4CompletedAug 200912

How it is read

Names in the registry

  • “Xanomeline/trospium chloride”, 2 entries
  • “Xanomeline/Trospium Chloride Capsule”, 2 entries
  • “Xanomeline/Trospium Chloride”, 2 entries
  • “Trospium Chloride”, 2 entries
  • “trospium chloride”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.